1
|
Abstract
Systemic lupus erythematosus (SLE) is a common autoimmune disease, which features the secretion of antibodies directed against autoantigens in vivo. In the present study, a peptide microarray was developed to detect the epitopes recognized by autoantibodies in patients with SLE for an effective method of diagnosis. SLE-associated epitopes in 14 autoantigens were predicted using the antigenic epitope prediction software DNA star. Peptides were synthesized based on the predicted antigenic epitopes and immobilized on a slide surface and developed into a peptide microarray. Using this peptide microarray the autoantibodies in 120 patients with SLE and 110 healthy subjects were detected. A total of 73 potential antigenic epitopes in 14 autoantigens were predicted and screened. The peptide microarray based on the 73 epitopes was used to detect the autoantibodies in patients with SLE. A total of 14 epitopes with potential diagnostic values were screened out. The sensitivity and specificity of the 14 epitopes for the diagnosis of SLE were 71.6 and 85.8%, respectively. An optimal set of epitopes for SLE diagnosis was obtained. As individual patients had a specific autoantibody spectrum it was possible to detect autoantibodies in SLE and perform the diagnosis of SLE using the peptide microarray.
Collapse
Affiliation(s)
- Xin Li
- Clinical Laboratory of Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China
| | - Haixia Li
- Clinical Laboratory of Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China
| | - Qiongdan Hu
- Department of Nephrology, The Traditional Chinese Medicine Hospital, Affiliated to Southwest Medical University, Luzhou, Sichuan 646000, P.R. China
| | - Jinfei Lin
- South China Institute of Microbial Ecology and Health, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China
| | - Qiong Zhang
- Clinical Laboratory of Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China
| | - Yao Li
- Clinical Laboratory of Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China
| | - Juan Li
- Department of Rheumatology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China
| | - Tao Chen
- South China Institute of Microbial Ecology and Health, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China
| | - Qiong Zhang
- Department of Nephrology, The Traditional Chinese Medicine Hospital, Affiliated to Southwest Medical University, Luzhou, Sichuan 646000, P.R. China
| | - Yurong Qiu
- Clinical Laboratory of Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China
| |
Collapse
|
2
|
Banjara M, Ghosh C, Dadas A, Mazzone P, Janigro D. Detection of brain-directed autoantibodies in the serum of non-small cell lung cancer patients. PLoS One 2017; 12:e0181409. [PMID: 28746384 PMCID: PMC5528996 DOI: 10.1371/journal.pone.0181409] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2016] [Accepted: 07/02/2017] [Indexed: 01/17/2023] Open
Abstract
Antibodies against brain proteins were identified in the plasma of cancer patients and are defined to cause paraneoplastic neurological syndromes. The profiles of brain-directed antibodies in non-small cell lung cancer (NSCLC) are largely unknown. Here, for the first time, we compared autoantibodies against brain proteins in NSCLC (n = 18) against those present in age-matched non-cancer control subjects (n = 18) with a similar life-style, habit, and medical history. Self-recognizing immunoglobulin (IgG) are primarily directed against cells in the cortex (P = 0.008), hippocampus (P = 0.003–0.05), and cerebellum (P = 0.02). More specifically, IgG targets were prominent in the pyramidal, Purkinje, and granule cell layers. Furthermore, autoimmune IgG signals were localized to neurons (81%), astrocytes (48%), and endothelial (29%) cells. While cancer sera yielded overall higher intensity signals, autoantigens of 100, 65, 45, 37, and 30 kDa molecular weights were the most represented. Additionally, a group of 100 kDa proteins seem more prevalent in female adenocarcinoma patients (4/5, 80%). In conclusion, our results revealed autoantigen specificity in NSCLC, which implicitly depends on patient’s demographics and disease history. Patients at risk for lung cancer but with no active disease revealed that the immune profile in NSCLC is disease-dependent.
Collapse
Affiliation(s)
- Manoj Banjara
- Cerebrovascular Research, Cleveland Clinic Lerner Research Institute, Cleveland Clinic, Cleveland, OH, United States of America
- Department of Biomedical Engineering, Cleveland Clinic Lerner Research Institute, Cleveland Clinic, Cleveland, OH, United States of America
| | - Chaitali Ghosh
- Cerebrovascular Research, Cleveland Clinic Lerner Research Institute, Cleveland Clinic, Cleveland, OH, United States of America
- Department of Biomedical Engineering, Cleveland Clinic Lerner Research Institute, Cleveland Clinic, Cleveland, OH, United States of America
- Department of Molecular Medicine, Cleveland Clinic Lerner Research Institute, Cleveland Clinic, Cleveland, OH, United States of America
- * E-mail: (DJ); (CG)
| | - Aaron Dadas
- Department of Biomedical Engineering, Ohio State University, Columbus, OH, United States of America
| | - Peter Mazzone
- Respiratory Centre, Cleveland Clinic, Cleveland, OH, United States of America
| | - Damir Janigro
- Flocel Inc., Cleveland, OH, United States of America
- Department of Physiology, Case Western Reserve University, Cleveland, OH, United States of America
- * E-mail: (DJ); (CG)
| |
Collapse
|
3
|
Mentese A, Fidan E, Alver A, Demir S, Yaman SO, Sumer A, Fidan S, Kavgaci H, Turan I. Detection of autoantibodies against carbonic anhydrase I and II in the plasma of patients with gastric cancer. Cent Eur J Immunol 2017; 42:73-7. [PMID: 28680333 DOI: 10.5114/ceji.2017.67320] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2016] [Accepted: 06/06/2016] [Indexed: 12/18/2022] Open
Abstract
Cancer is the second leading cause of death and gastric cancer is the fourth most common cancer type worldwide. Investigation of autoantibodies in cancer patients has been a popular research area in recent years. The aim of the current study was to investigate carbonic anhydrase I and II (CA I and II) autoantibodies in the plasma of subjects with gastric cancer based on the information and considerations of autoimmune relation of gastric cancer. Anti-CA I and II antibody levels were investigated by ELISA in plasma samples of fifty two patients with gastric cancer and thirty five healthy peers. Anti-CA I and II antibody titers of the gastric cancer group were significantly higher compared with the control group (p = 0.004, p = 0.0001, respectively). Plasma anti-CA I levels of the metastatic group were lower than the non-metastatic group and this difference was found statistically significant (p < 0.05), but there was no statistical difference between plasma anti-CA II levels of the groups. CA I and II autoantibody titers in patients with gastric cancer were found higher compared to healthy subjects and the results suggest that these autoantibodies may be involved in the pathogenesis of gastric cancer.
Collapse
|
4
|
Menteşe A, Erkut N, Demir S, Özer Yaman S, Sümer A, Doğramacı Ş, Alver A, Sönmez M. Autoantibodies Against Carbonic Anhydrase I and II in Patients with Acute Myeloid Leukemia. Turk J Haematol 2017; 34:307-313. [PMID: 28270370 PMCID: PMC5774362 DOI: 10.4274/tjh.2016.0341] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022] Open
Abstract
OBJECTIVE Cancer, one of the principal causes of death, is a global social health problem. Autoantibodies developed against the organism's self-antigens are detected in the sera of subjects with cancer. In recent years carbonic anhydrase (CA) I and II autoantibodies have been shown in some autoimmune diseases and carcinomas, but the mechanisms underlying this immune response have not yet been explained. The aim of this study was to evaluate CA I and II autoantibodies in patients with acute myeloid leukemia (AML) and to provide a novel perspective regarding the autoimmune basis of the disease. MATERIALS AND METHODS Anti-CA I and II antibody levels were investigated using ELISA in serum samples from 30 patients with AML and 30 healthy peers. RESULTS Anti-CA I and II antibody titers in the AML group were significantly higher compared with the control group (p=0.0001 and 0.018, respectively). A strong positive correlation was also determined between titers of anti-CA I and II antibodies (r=0.613, p=0.0001). CONCLUSION Our results suggest that these autoantibodies may be involved in the pathogenesis of AML. More extensive studies are now needed to reveal the entire mechanism.
Collapse
Affiliation(s)
- Ahmet Menteşe
- Karadeniz Technical University Vocational School of Health Sciences, Program of Medical Laboratory Techniques, Trabzon, Turkey
| | - Nergiz Erkut
- Karadeniz Technical University Faculty of Medicine, Department of Hematology, Trabzon, Turkey
| | - Selim Demir
- Karadeniz Technical University Faculty of Health Sciences, Department of Nutrition and Dietetics, Trabzon, Turkey
| | - Serap Özer Yaman
- Karadeniz Technical University Faculty of Medicine, Department of Medical Biochemistry, Trabzon, Turkey
| | - Ayşegül Sümer
- Recep Tayyip Erdoğan University Faculty of Health Services, Department of Nursing, Rize, Turkey
| | - Şeniz Doğramacı
- Karadeniz Technical University Faculty of Medicine, Department of Medical Biochemistry, Trabzon, Turkey
| | - Ahmet Alver
- Karadeniz Technical University Faculty of Medicine, Department of Medical Biochemistry, Trabzon, Turkey.,Recep Tayyip Erdoğan University Faculty of Medicine, Department of Medical Biochemistry, Rize, Turkey
| | - Mehmet Sönmez
- Karadeniz Technical University Faculty of Medicine, Department of Hematology, Trabzon, Turkey
| |
Collapse
|
5
|
Zheng T, Pierre-Pierre N, Yan X, Huo Q, Almodovar AJO, Valerio F, Rivera-Ramirez I, Griffith E, Decker DD, Chen S, Zhu N. Gold nanoparticle-enabled blood test for early stage cancer detection and risk assessment. ACS Appl Mater Interfaces 2015; 7:6819-27. [PMID: 25757512 DOI: 10.1021/acsami.5b00371] [Citation(s) in RCA: 74] [Impact Index Per Article: 8.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/19/2023]
Abstract
When citrate ligands-capped gold nanoparticles are mixed with blood sera, a protein corona is formed on the nanoparticle surface due to the adsorption of various proteins in the blood to the nanoparticles. Using a two-step gold nanoparticle-enabled dynamic light scattering assay, we discovered that the amount of human immunoglobulin G (IgG) in the gold nanoparticle protein corona is increased in prostate cancer patients compared to noncancer controls. Two pilot studies conducted on blood serum samples collected at Florida Hospital and obtained from Prostate Cancer Biorespository Network (PCBN) revealed that the test has a 90-95% specificity and 50% sensitivity in detecting early stage prostate cancer, representing a significant improvement over the current PSA test. The increased amount of human IgG found in the protein corona is believed to be associated with the autoantibodies produced in cancer patients as part of the immunodefense against tumor. Proteomic analysis of the nanoparticle protein corona revealed molecular profile differences between cancer and noncancer serum samples. Autoantibodies and natural antibodies produced in cancer patients in response to tumorigenesis have been found and detected in the blood of many cancer types. The test may be applicable for early detection and risk assessment of a broad spectrum of cancer. This new blood test is simple, low cost, requires only a few drops of blood sample, and the results are obtained within minutes. The test is well suited for screening purpose. More extensive studies are being conducted to further evaluate and validate the clinical potential of the new test.
Collapse
Affiliation(s)
| | | | | | | | - Alvin J O Almodovar
- ∥Florida Hospital Cancer Institute, Research and Development, 2501 North Orange Avenue, Suite 247, Orlando, Florida 32804, United States
| | - Felipe Valerio
- ∥Florida Hospital Cancer Institute, Research and Development, 2501 North Orange Avenue, Suite 247, Orlando, Florida 32804, United States
| | - Inoel Rivera-Ramirez
- ∥Florida Hospital Cancer Institute, Research and Development, 2501 North Orange Avenue, Suite 247, Orlando, Florida 32804, United States
| | - Elizabeth Griffith
- ∥Florida Hospital Cancer Institute, Research and Development, 2501 North Orange Avenue, Suite 247, Orlando, Florida 32804, United States
| | - David D Decker
- ∥Florida Hospital Cancer Institute, Research and Development, 2501 North Orange Avenue, Suite 247, Orlando, Florida 32804, United States
| | - Sixue Chen
- ⊥Department of Biology, Genetics Institute, Plant Molecular and Cellular Biology Program, University of Florida, Gainesville, Florida 32610, United States
| | - Ning Zhu
- ⊥Department of Biology, Genetics Institute, Plant Molecular and Cellular Biology Program, University of Florida, Gainesville, Florida 32610, United States
| |
Collapse
|